PatientsVille.com Logo


Malaria Medical Research Studies

Up-to-date List of Malaria Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Malaria Medical Research Studies

Rank Status Study
1 Recruiting Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Condition: Malaria
Interventions: Drug: Malarone (atovaquone + proguanil combination);   Drug: RIAMET (artemether + LUMEFANTRIN combination)
Outcome Measures: Number of cases where a second line treatment is used for either intolerance or lack of effectiveness;   Parasitological cure rate;   Fever clearance;   Digestive tolerance;   Number of relapses
2 Not yet recruiting Defining the Micro-epidemiology and Elimination Strategy of Falciparum Malaria in Areas of Artemisinin Resistance
Condition: Plasmodium Falciparum Malaria
Intervention: Drug: Malaria elimination using DP and low-dose primaquine
Outcome Measures: prevalence of falciparum Malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine.;   Safety and acceptability of targeted Malaria elimination
3 Recruiting Time to Become Negative of Three Rapid Diagnostic Tests for Malaria
Condition: Malaria, Falciparum
Outcome Measures: To estimate the proportion of positive tests in patients successfully treated for Malaria (smear negative) at different time points after treatment, for three rapid diagnostic tests: two HRP2 test and one pLDH test.;   To measure the sensitivity and specificity of the Malaria rapid tests compared to smear microscopy.;   To estimate the median time to become negative for each of the rapid diagnostic test.;   To estimate the proportion of positive tests among smear negative results and the median time to become negative according to the initial parasitaemia and the presence of gametocytes.
4 Recruiting Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana
Conditions: Malaria;   Anaemia
Interventions: Drug: Artemether-lumefantrine combination;   Drug: Dihydroartemisinin Piperaquine combination;   Drug: Amodiaquine plus sulphadoxine-pyrimethamine combination
Outcome Measures: Incidence of Malaria cases;   Proportion of children with parasitaemia;   Proportion of children with anaemia;   Number of referrals;   Incidence of severe illness;   Incidence of adverse events
5 Recruiting Malaria in Early Life Study
Conditions: Plasmodium Falciparum Malaria;   Plasmodium Vivax Malaria
Intervention: Drug: dihydroartemisinin-piperaquine
Outcome Measures: The incidence of clinical Malaria in the first year of life;   Proportion of infant with recurrent parasitaemia due to any species at day 42 after treatment with DHP.
6 Not yet recruiting Community-based Scheduled Screening and Treatment of Malaria in Pregnancy for Improved Maternal and Infant Health: a Cluster-randomized Trial in The Gambia, Burkina Faso and Benin
Conditions: Malaria, Antepartum;   Maternal Malaria During Pregnancy - Baby Not Yet Delivered;   Small for Gestational Age (Disorder)
Intervention: Other: community based screening and treatment
Outcome Measures: Placental Malaria;   Birth weight
7 Recruiting ANC & Malaria Diagnostic in Pregnancy
Condition: Malaria
Intervention: Drug: ASAQ
Outcome Measures: Placental Malaria at delivery;   The proportion of women with peripheral positive Malaria infection at delivery
8 Recruiting Evaluating the Ottawa Malaria Decision Aid
Condition: Malaria
Intervention: Other: Ottawa Malaria Decision Aid
Outcome Measures: Travellers' Knowledge Score;   Decisional Conflict Score;   Preparation for Decision-making Score;   Medication Adherence Score
9 Unknown  Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine
Condition: Malaria
Interventions: Biological: MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP;   Biological: Verorab vaccine
Outcome Measures: Number of clinical Malaria episodes occurring during the consecutive Malaria transmission season after the third vaccination;   Solicited adverse events measured from day 0 to day 7 after each dose;   Unsolicited adverse events measured up to one month after each dose;   Serious Adverse Events measured during the 12 months of study duration;   The humoral response to the vaccine antigen: assessed by measuring the level of IgG by ELISA;   IgG ability to recognize the native protein on Merozoite using Western Blot(WB) method;   Incidence of all clinical Malaria episodes occurring through two transmission seasons subsequent to the 3 doses.
10 Recruiting Chloroquine for Malaria in Pregnancy
Condition: Malaria
Interventions: Drug: sulfadoxine/pyrimethamine;   Drug: Chloroquine
Outcome Measures: Incidence of placental Malaria infection based on histology.;   Incidence of low birth weight (LBW) (birthweight < 2500 grams);   Incidence of intrauterine growth restriction (IUGR) (weight <10th percentile gestational age based on the World Health Organization (WHO) fetal growth curve);   Incidence of placental Malaria infection diagnosed by placental impression smear.;   Per arm: Incidence of clinical Malaria, all species.;   Per arm: Incidence of Malaria infection, all species.;   Incidence of active placental Malaria infection diagnosed by the presence of parasites and/or pigment on histological section.;   Infant mortality rate to 14 weeks of age;   Incidence of preterm delivery;   Incidence of miscarriage (estimated gestational age <28 weeks);   Incidence of stillbirth;   Incidence of maternal severe anemia (hemoglobin < 7gm/dl);   Incidence of maternal anemia (hemoglobin < 10gm/dl);   Incidence of infection in the fetal circulation based on the results of the thick smear and polymerase chain reaction (PCR) from the cord blood sample.
11 Unknown  Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness
Conditions: Fever;   Malaria
Intervention: Device: Field microscopy and Paracheck Pf®
Outcome Measures: diagnostic test validity; unit cost per Malaria case diagnosed and treated with Artemether-Lumefantrine; total savings associated with treatment of confirmed Malaria cases; compliance with directives for use of rapid test or microscopy;   unit cost of non-Malaria febrile treatment; therapeutic behaviour in light of pressure to prescribe antiMalarials
12 Unknown  Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine
Condition: Malaria
Interventions: Biological: GMZ2 (Malaria vaccine);   Biological: GMZ2 Malaria vaccine;   Biological: Verorab vaccine
Outcome Measures: Local and systemic reactogenicity;   Unsolicited adverse events;   Occurrence of serious adverse events;   Biological safety;   Humoral immune response to GLURP and MSP 3;   Cellural immune response
13 Unknown  The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children
Condition: Malaria
Intervention: Drug: Amodiaquine plus Artesunate co-administration
Outcome Measures: Incidence rate of clinical episodes of Malaria per child per year;   Prevalence of peripheral parasitaemia;   Prevalence of anaemia;   Parasite density (geometric means);   Proportions adhering to strategies;   Incidence of adverse drug effects within 7 days after intervention
14 Recruiting Optimal Fluid Management in Adult Severe Malaria
Conditions: Malaria;   Sepsis
Outcome Measures: Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index;   Association between the GEDVI,after conventional fluid resuscitation, and (1) serum creatinine level, (2) EVLWI;   Correlation between GEDVI and changes over time in plasma lactate level;   Change in central venous oxygen saturation (ScvO2) in relation to GEDVI and its association with acid-base status;   Incidence of pulmonary edema and ALI/ARDS;   Incidence of AKI and induction rate of renal replacement therapy;   Time course of hemodynamic parameters in relation to fluid therapy;   Time course of respiratory parameters in relation to fluid therapy;   Parasite burden in adults with severe Malaria in relation to organ damage (renal, pulmonary);   Evaluation of Biomarkers for early detection of ARDS;   Correlation between GEDVI and clinical variables;   Evaluation of the fluid requirements for resuscitation in patients with severe Malaria or sepsis
15 Recruiting Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy
Condition: Malaria
Interventions: Drug: dihydroartemisinin-piperaquine;   Drug: Artesunate-mefloquine;   Drug: arthemeter-lumefantrin
Outcome Measures: Cure rate defined as clearance of asexual parasites without recurrence within the period between treatment and delivery or a 63 day period;   Number of adverse events;   Biochemical and haematological changes;   Kinetic parameters of artesunate, mefloquine, piperaquine and lumefantrine;   Anaemia;   Gametocyte carriage;   Changes in the Reticulocyte counts;   Malaria infection rate at delivery and placental parasitaemia;   Pregnancy outcomes (abortions, low birth weight, premature birth, congenital abnormality, stillbirths, neonatal and infant mortality);   Infant growth and development at 1 year of life
16 Not yet recruiting IMPROV (Improving the Radical Cure of Vivax Malaria)
Condition: Uncomplicated Vivax Malaria
Interventions: Drug: Primaquine;   Drug: Placebo
Outcome Measures: Incidence rate (per person-year) of symptomatic recurrent P. vivax;   The incidence rate (per person-year) of any recurrent P. vivax Malaria.;   Incidence risk of any recurrent symptomatic of P. vivax Malaria compared to control arm;   The Haematological recovery in patients with vivax Malaria;   Proportion of patients with Serious Adverse Drug reactions;   Primaquine tolerability;   Primaquine tolerability comparison between patients in intervention arm and control arm;   Incidence risk of severe anaemia in G6PD deficient arm;   Cost effective analysis in the management of P. vivax with respect to the use of G6PD tests
17 Recruiting Ultrasound Study in Pregnant Women With Malaria
Conditions: Pregnant Women;   Malaria
Outcome Measures: Ultrasound measurements;   Examination of all newborns
18 Recruiting A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria
Condition: Plasmodium Falciparum Malaria
Intervention: Biological: FMP2.1/AS01B
Outcome Measure: PCR-derived parasite multiplication rate (PMR)
19 Unknown  A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Conditions: Uncomplicated Falciparum Malaria;   Vivax Malaria
Interventions: Drug: Dihydroartemisinin + Piperaquine (Artekin);   Drug: artesunate-sulphadoxin/pyrimethamine, chloroquine
Outcome Measures: PCR corrected adequate clinical and parasitological response (PCR corrected 'adequate clinical and parasitological response' or ACPR);   Crude or PCR uncorrected ACPR;   Early treatment failure (failure to clear parasitaemia);   fever clearance times;   parasite clearance times with no recrudescence over the observation period;   gametocyte clearance times;   Haemoglobin levels on day 14 compared to admission;   safety and tolerability (rate and severity of adverse events)
20 Unknown  Randomized Trial of Erythropoietin During Cerebral Malaria
Condition: Cerebral Malaria
Interventions: Drug: Placebo;   Drug: Erythropoietin
Outcome Measure: Survival

These studies may lead to new treatments and are adding insight into Malaria etiology and treatment.

A major focus of Malaria research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Malaria